Pharmacokinetics, Safety and Efficacy Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids
PK of 25 mg and 50 mg Proellex® administered once daily (QD) over a 4-month period.
Uterine Fibroids
DRUG: Proellex 25 mg|DRUG: Proellex 50 mg|DRUG: Lupron Depot
The Primary Outcome Measure is the PK Characteristics of 25 mg and 50 mg Proellex., 4 months
The primary objective is to evaluate the pharmacokinetics (PK) of 25 mg and 50 mg Proellex® administered once daily (QD) over a 4-month period.